PT  - JOURNAL ARTICLE
AU  - Rizzo, Toni
ED  - Raungaard, Bent
TI  - SORT-OUT VI: Zotarolimus-Eluting Stent Noninferior to Biolimus-Eluting Stent
DP  - 2013  01
TA  - MD Conference Express
PG  - 17--18
VI  - 13
IP  - 19
4099  - http://mdc.sagepub.com/content/13/19/17.short
4100  - http://mdc.sagepub.com/content/13/19/17.full
AB  - First-generation drug-eluting stents have reduced the risk of restenosis compared with bare-metal stents; however, these stents may have increased risk of stent thrombosis. Newer generation drug-eluting stents, which are constructed with biocompatible or biodegradable polymers, may have greater efficacy, safety, and device performance. The Randomized Clinical Comparison of Biomatrix Flex and Resolute Integrity trial [SORT-OUT VI; NCT01956448] compared the efficacy and safety of a zotarolimus-eluting stent with a biolimus-eluting stent in a population-based setting.